Literature DB >> 8197768

Does the method of management of papillary thyroid carcinoma make a difference in outcome?

L J DeGroot1, E L Kaplan, F H Straus, M S Shukla.   

Abstract

We have analyzed data on a group of 269 patients with papillary thyroid carcinoma followed on average for 12 years to determine (1) if a prognostic classification scheme can be used to predict an appropriate surgical approach; (2) the effect of treatment on prognosis; and (3) if patients with a "excellent" prognosis benefit from more extensive surgical resection and 131I ablation. Prognostic classification schemes developed by the American Joint Commission, Cady et al., Hay et al., the European Thyroid Association, and our own clinical class scheme each appropriately divided patients into risk category groups. With each system, some patients classified in the low risk group eventually died of the tumor. Considering the excellent but not perfect precision of the prognostic schemes, the need for detailed pathologic analysis, and ideally postoperative thyroid scanning, we conclude that the prognostic classification schemes do not allow the decision at the operating table regarding the appropriate extent of surgery. Patients followed at our institution, operated on by one of three experienced surgeons, and usually given 131I ablation were compared to other patients in the follow-up group operated on by other surgeons and not routinely ablated. There were significantly fewer deaths and recurrences among the patients managed by our method. However, when the groups were restricted to those considering only patients who had more extensive surgery, postoperative 131I ablation, or both, the differences between the groups became insignificant. This finding indicates that the difference in prognosis, comparing patients treated at our institution and those initially treated elsewhere, was primarily due to the routine use of more extensive surgery and postoperative radioactive iodide ablation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8197768     DOI: 10.1007/bf00348202

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  5 in total

1.  Papillary thyroid carcinoma.

Authors:  I D Hay
Journal:  Endocrinol Metab Clin North Am       Date:  1990-09       Impact factor: 4.741

2.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group.

Authors:  D P Byar; S B Green; P Dor; E D Williams; J Colon; H A van Gilse; M Mayer; R J Sylvester; M van Glabbeke
Journal:  Eur J Cancer       Date:  1979-08       Impact factor: 9.162

3.  An expanded view of risk-group definition in differentiated thyroid carcinoma.

Authors:  B Cady; R Rossi
Journal:  Surgery       Date:  1988-12       Impact factor: 3.982

4.  Natural history, treatment, and course of papillary thyroid carcinoma.

Authors:  L J DeGroot; E L Kaplan; M McCormick; F H Straus
Journal:  J Clin Endocrinol Metab       Date:  1990-08       Impact factor: 5.958

5.  Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system.

Authors:  I D Hay; C S Grant; W F Taylor; W M McConahey
Journal:  Surgery       Date:  1987-12       Impact factor: 3.982

  5 in total
  10 in total

1.  Extent of surgery for differentiated thyroid cancer: recommended guideline.

Authors:  Ganiyu A Rahman
Journal:  Oman Med J       Date:  2011-01

Review 2.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

3.  [Need for thyroidectomy in differentiated thyroid cancers].

Authors:  S Samel; C Käufer
Journal:  Langenbecks Arch Chir       Date:  1995

4.  Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution.

Authors:  Christian Passler; Gerhard Prager; Christian Scheuba; Klaus Kaserer; Georg Zettinig; Bruno Niederle
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

5.  Excellent prognosis of patients with solitary T1N0M0 papillary thyroid carcinoma who underwent thyroidectomy and elective lymph node dissection without radioiodine therapy.

Authors:  Yasuhiro Ito; Hiroo Masuoka; Mitsuhiro Fukushima; Hiroyuki Inoue; Minoru Kihara; Chisato Tomoda; Takuya Higashiyama; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya; Akira Miyauchi
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

6.  Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer.

Authors:  Poorni M Manohar; Lauren J Beesley; Emily L Bellile; Francis P Worden; Anca M Avram
Journal:  Clin Nucl Med       Date:  2018-09       Impact factor: 7.794

7.  A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis.

Authors:  Georgios Antonios Margonis; Mario Samaha; Yuhree Kim; Lauren McLendon Postlewait; Pamela Kunz; Shishir Maithel; Thuy Tran; Nickolas Berger; T Clark Gamblin; Matthew G Mullen; Todd W Bauer; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2016-03-23       Impact factor: 3.452

8.  Thyroid cancer: burden of illness and management of disease.

Authors:  Rebecca L Brown; Jonas A de Souza; Ezra Ew Cohen
Journal:  J Cancer       Date:  2011-04-04       Impact factor: 4.207

9.  Analysis of clinical outcome of patients with poorly differentiated thyroid carcinoma.

Authors:  Katsuhiro Tanaka; Hiroshi Sonoo; Wataru Saito; Yusuke Ohta; Toshiro Shimo; Mai Sohda; Yutaka Yamamoto; Junichi Kurebayashi
Journal:  ISRN Endocrinol       Date:  2011-03-29

10.  Second primary neoplasms in thyroid cancer patients.

Authors:  K Ishikawa; S Noguchi; K Tanaka; A Fukuda; T Hirohata
Journal:  Jpn J Cancer Res       Date:  1996-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.